Timothy Garvey, EASD 2022: STEP clinical trial programme: Semaglutide 2.4 mg treatment in people with obestiy
The effect of once-weekly semaglutide 2.4 mg on the risk of developing type 2 diabetes (T2D) in people with obesity is unknown. Using data from the Semaglutide Treatment Effect in People with obesity (STEP) programme (STEP 1 and STEP 4) the risk of developing T2D over 10 years was assessed. In this touchENDOCRINOLOGY interview, Prof. Timothy Garvey (University of Alabama, Birmingham, AL, USA) discusses the impact of semaglutide on the risk of developing T2D and the implications of these findings for the future clinical use.
The abstract entitled: ‘Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- Could you give us a brief overview of the STEP clinical trial programme? (0:22)
- What was the impact of semaglutide treatment on the risk of developing T2D in STEP 1 and STEP 4? (1:16)
- What are the implications of these findings for the future clinical use of semaglutide? (3:00)
Disclosures: Timothy Garvey discloses grant/research support from Eli Lilly, Epitomee, Novo Nordisk, Pfizer.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
